You are using an outdated browser. For a faster, safer browsing experience, upgrade for free today.

Medical Care

Global Waldenstrom Macroglobulinemia Therapeutics Market Research Report 2021, Competitive Analysis, Industry Growth Trends And Forecast 2027

Market Analysis and Insights: Global Waldenstrom Macroglobulinemia Therapeutics Market
The research report studies the Waldenstrom Macroglobulinemia Therapeutics market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Waldenstrom Macroglobulinemia Therapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
Global Waldenstrom Macroglobulinemia Therapeutics Scope and Segment
The global Waldenstrom Macroglobulinemia Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Waldenstrom Macroglobulinemia Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
CB-839
Copanlisib Hydrochloride
DI-B4
Entospletinib
Everolimus
FV-162
Others
by Application, this report covers the following segments
Clinic
Hospital
Others
Global Waldenstrom Macroglobulinemia Therapeutics market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Waldenstrom Macroglobulinemia Therapeutics key players in this market include:
BeiGene(Beijing) Co Ltd
Calithera Biosciences, Inc.
Celgene Corporation
Genentech, Inc.
Genmab A/S
Gilead Sciences, Inc.
Hutchison MediPharma Limited
Idera Pharmaceuticals, Inc.
IGF Oncology, LLC.
Incyte Corporation
Karyopharm Therapeutics, Inc.
Merck KGaA
Millennium Pharmaceuticals, Inc.
1 Market Overview of Waldenstrom Macroglobulinemia Therapeutics
1.1 Waldenstrom Macroglobulinemia Therapeutics Market Overview
1.1.1 Waldenstrom Macroglobulinemia Therapeutics Product Scope
1.1.2 Waldenstrom Macroglobulinemia Therapeutics Market Status and Outlook
1.2 Global Waldenstrom Macroglobulinemia Therapeutics Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Waldenstrom Macroglobulinemia Therapeutics Market Size by Region (2016-2027)
1.4 Global Waldenstrom Macroglobulinemia Therapeutics Historic Market Size by Region (2016-2021)
1.5 Global Waldenstrom Macroglobulinemia Therapeutics Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Waldenstrom Macroglobulinemia Therapeutics Market Size (2016-2027)
1.6.1 North America Waldenstrom Macroglobulinemia Therapeutics Market Size (2016-2027)
1.6.2 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size (2016-2027)
1.6.3 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size (2016-2027)
1.6.4 Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size (2016-2027)
1.6.5 Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size (2016-2027)
2 Waldenstrom Macroglobulinemia Therapeutics Market Overview by Type
2.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Waldenstrom Macroglobulinemia Therapeutics Historic Market Size by Type (2016-2021)
2.3 Global Waldenstrom Macroglobulinemia Therapeutics Forecasted Market Size by Type (2022-2027)
2.4 CB-839
2.5 Copanlisib Hydrochloride
2.6 DI-B4
2.7 Entospletinib
2.8 Everolimus
2.9 FV-162
2.10 Others
3 Waldenstrom Macroglobulinemia Therapeutics Market Overview by Application
3.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Waldenstrom Macroglobulinemia Therapeutics Historic Market Size by Application (2016-2021)
3.3 Global Waldenstrom Macroglobulinemia Therapeutics Forecasted Market Size by Application (2022-2027)
3.4 Clinic
3.5 Hospital
3.6 Others
4 Waldenstrom Macroglobulinemia Therapeutics Competition Analysis by Players
4.1 Global Waldenstrom Macroglobulinemia Therapeutics Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Waldenstrom Macroglobulinemia Therapeutics as of 2020)
4.3 Date of Key Players Enter into Waldenstrom Macroglobulinemia Therapeutics Market
4.4 Global Top Players Waldenstrom Macroglobulinemia Therapeutics Headquarters and Area Served
4.5 Key Players Waldenstrom Macroglobulinemia Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Waldenstrom Macroglobulinemia Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 BeiGene(Beijing) Co Ltd
5.1.1 BeiGene(Beijing) Co Ltd Profile
5.1.2 BeiGene(Beijing) Co Ltd Main Business
5.1.3 BeiGene(Beijing) Co Ltd Waldenstrom Macroglobulinemia Therapeutics Products, Services and Solutions
5.1.4 BeiGene(Beijing) Co Ltd Waldenstrom Macroglobulinemia Therapeutics Revenue (US$ Million) & (2016-2021)
5.1.5 BeiGene(Beijing) Co Ltd Recent Developments
5.2 Calithera Biosciences Inc.
5.2.1 Calithera Biosciences Inc. Profile
5.2.2 Calithera Biosciences Inc. Main Business
5.2.3 Calithera Biosciences Inc. Waldenstrom Macroglobulinemia Therapeutics Products, Services and Solutions
5.2.4 Calithera Biosciences Inc. Waldenstrom Macroglobulinemia Therapeutics Revenue (US$ Million) & (2016-2021)
5.2.5 Calithera Biosciences Inc. Recent Developments
5.3 Celgene Corporation
5.3.1 Celgene Corporation Profile
5.3.2 Celgene Corporation Main Business
5.3.3 Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Products, Services and Solutions
5.3.4 Celgene Corporation Waldenstrom Macroglobulinemia Therapeutics Revenue (US$ Million) & (2016-2021)
5.3.5 Genentech Inc. Recent Developments
5.4 Genentech Inc.
5.4.1 Genentech Inc. Profile
5.4.2 Genentech Inc. Main Business
5.4.3 Genentech Inc. Waldenstrom Macroglobulinemia Therapeutics Products, Services and Solutions
5.4.4 Genentech Inc. Waldenstrom Macroglobulinemia Therapeutics Revenue (US$ Million) & (2016-2021)
5.4.5 Genentech Inc. Recent Developments
5.5 Genmab A/S
5.5.1 Genmab A/S Profile
5.5.2 Genmab A/S Main Business
5.5.3 Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Products, Services and Solutions
5.5.4 Genmab A/S Waldenstrom Macroglobulinemia Therapeutics Revenue (US$ Million) & (2016-2021)
5.5.5 Genmab A/S Recent Developments
5.6 Gilead Sciences Inc.
5.6.1 Gilead Sciences Inc. Profile
5.6.2 Gilead Sciences Inc. Main Business
5.6.3 Gilead Sciences Inc. Waldenstrom Macroglobulinemia Therapeutics Products, Services and Solutions
5.6.4 Gilead Sciences Inc. Waldenstrom Macroglobulinemia Therapeutics Revenue (US$ Million) & (2016-2021)
5.6.5 Gilead Sciences Inc. Recent Developments
5.7 Hutchison MediPharma Limited
5.7.1 Hutchison MediPharma Limited Profile
5.7.2 Hutchison MediPharma Limited Main Business
5.7.3 Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Products, Services and Solutions
5.7.4 Hutchison MediPharma Limited Waldenstrom Macroglobulinemia Therapeutics Revenue (US$ Million) & (2016-2021)
5.7.5 Hutchison MediPharma Limited Recent Developments
5.8 Idera Pharmaceuticals Inc.
5.8.1 Idera Pharmaceuticals Inc. Profile
5.8.2 Idera Pharmaceuticals Inc. Main Business
5.8.3 Idera Pharmaceuticals Inc. Waldenstrom Macroglobulinemia Therapeutics Products, Services and Solutions
5.8.4 Idera Pharmaceuticals Inc. Waldenstrom Macroglobulinemia Therapeutics Revenue (US$ Million) & (2016-2021)
5.8.5 Idera Pharmaceuticals Inc. Recent Developments
5.9 IGF Oncology, LLC.
5.9.1 IGF Oncology, LLC. Profile
5.9.2 IGF Oncology, LLC. Main Business
5.9.3 IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Products, Services and Solutions
5.9.4 IGF Oncology, LLC. Waldenstrom Macroglobulinemia Therapeutics Revenue (US$ Million) & (2016-2021)
5.9.5 IGF Oncology, LLC. Recent Developments
5.10 Incyte Corporation
5.10.1 Incyte Corporation Profile
5.10.2 Incyte Corporation Main Business
5.10.3 Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Products, Services and Solutions
5.10.4 Incyte Corporation Waldenstrom Macroglobulinemia Therapeutics Revenue (US$ Million) & (2016-2021)
5.10.5 Incyte Corporation Recent Developments
5.11 Karyopharm Therapeutics Inc.
5.11.1 Karyopharm Therapeutics Inc. Profile
5.11.2 Karyopharm Therapeutics Inc. Main Business
5.11.3 Karyopharm Therapeutics Inc. Waldenstrom Macroglobulinemia Therapeutics Products, Services and Solutions
5.11.4 Karyopharm Therapeutics Inc. Waldenstrom Macroglobulinemia Therapeutics Revenue (US$ Million) & (2016-2021)
5.11.5 Karyopharm Therapeutics Inc. Recent Developments
5.12 Merck KGaA
5.12.1 Merck KGaA Profile
5.12.2 Merck KGaA Main Business
5.12.3 Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Products, Services and Solutions
5.12.4 Merck KGaA Waldenstrom Macroglobulinemia Therapeutics Revenue (US$ Million) & (2016-2021)
5.12.5 Merck KGaA Recent Developments
5.13 Millennium Pharmaceuticals Inc.
5.13.1 Millennium Pharmaceuticals Inc. Profile
5.13.2 Millennium Pharmaceuticals Inc. Main Business
5.13.3 Millennium Pharmaceuticals Inc. Waldenstrom Macroglobulinemia Therapeutics Products, Services and Solutions
5.13.4 Millennium Pharmaceuticals Inc. Waldenstrom Macroglobulinemia Therapeutics Revenue (US$ Million) & (2016-2021)
5.13.5 Millennium Pharmaceuticals Inc. Recent Developments
6 North America
6.1 North America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Waldenstrom Macroglobulinemia Therapeutics Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Waldenstrom Macroglobulinemia Therapeutics Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Waldenstrom Macroglobulinemia Therapeutics Market Dynamics
11.1 Waldenstrom Macroglobulinemia Therapeutics Industry Trends
11.2 Waldenstrom Macroglobulinemia Therapeutics Market Drivers
11.3 Waldenstrom Macroglobulinemia Therapeutics Market Challenges
11.4 Waldenstrom Macroglobulinemia Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
  • FORMAT: PDF
  • PUBLISHED DATE: Apr, 2021
  • NO OF PAGES: 125